Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen

Vaccine

Volumn 35, Issue 8, 2017, Pages 1140-1147

  Andersson, Anne Marie C ^a   Resende, Mafalda ^a   Salanti, Ali ^a   Nielsen, Morten A ^a   Holst, Peter J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adenoviral vectors; Placental malaria; Prime boost regimens; VAR2CSA; Virus like particles

Indexed keywords

ANTIGEN; ENVELOPE PROTEIN; GAG PROTEIN; HEMAGGLUTININ; UNCLASSIFIED DRUG; VAR2CSA ANTIGEN; CHONDROITIN SULFATE; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; MALARIA VACCINE; PARASITE ANTIGEN; PROTEIN BINDING; PROTOZOON ANTIBODY; VAR2CSA PROTEIN, PLASMODIUM FALCIPARUM; VIRUS LIKE PARTICLE VACCINE;

ADENOVIRIDAE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A; MOUSE; MOUSE MAMMARY TUMOR VIRUS; NONHUMAN; PLACENTA MALARIA; PRIORITY JOURNAL; PROTEIN MODIFICATION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; ERYTHROCYTE; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; MALARIA FALCIPARUM; PARASITOLOGY; PLACENTA; PLASMODIUM FALCIPARUM; PREGNANCY;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHONDROITIN SULFATES; ERYTHROCYTES; FEMALE; GENE PRODUCTS, GAG; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION; MALARIA VACCINES; MALARIA, FALCIPARUM; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED BALB C; PLACENTA; PLASMODIUM FALCIPARUM; PREGNANCY; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 85010618810     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.01.016     Document Type: Article

References (47)

1. [1] WHO. From over 90,000 cases to zero in two decades: the European Region is malaria free; 2016.
2. [2] WHO. World Malaria report 2015. WHO; 2015.
3. [3] Moya-Alvarez, V., Abellana, R., Cot, M., Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. Malar J, 13, 2014, 271.
4. [4] Desai, M., ter Kuile, F.O., Nosten, F., McGready, R., Asamoa, K., Brabin, B., et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7 (2007), 93–104.
5. [5] Steketee, R.W., Nahlen, B.L., Parise, M.E., Menendez, C., The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 64 (2001), 28–35.
6. [6] Fried, M., Nosten, F., Brockman, A., Brabin, B.J., Duffy, P.E., Maternal antibodies block malaria. Nature 395 (1998), 851–852.
7. [7] Crompton, P.D., Moebius, J., Portugal, S., Waisberg, M., Hart, G., Garver, L.S., et al. Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. Annu Rev Immunol 32 (2014), 157–187.
8. [8] Rask, T.S., Hansen, D.A., Theander, T.G., Gorm Pedersen, A., Lavstsen, T., Plasmodium falciparum erythrocyte membrane protein 1 diversity in seven genomes–divide and conquer. PLoS Comput Biol, 6, 2010.
9. [9] Salanti, A., Dahlback, M., Turner, L., Nielsen, M.A., Barfod, L., Magistrado, P., et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 200 (2004), 1197–1203.
10. [10] Clausen, T.M., Christoffersen, S., Dahlback, M., Langkilde, A.E., Jensen, K.E., Resende, M., et al. Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria. J Biol Chem 287 (2012), 23332–23345.
11. [11] Srivastava, A., Gangnard, S., Dechavanne, S., Amirat, F., Lewit Bentley, A., Bentley, G.A., et al. Var2CSA minimal CSA binding region is located within the N-terminal region. PLoS ONE, 6, 2011, e20270.
12. [12] Fernandez, P., Petres, S., Mecheri, S., Gysin, J., Scherf, A., Strain-transcendent immune response to recombinant Var2CSA DBL5-epsilon domain block P. falciparum adhesion to placenta-derived BeWo cells under flow conditions. PLoS ONE, 5, 2010, e12558.
13. [13] Nielsen, M.A., Pinto, V.V., Resende, M., Dahlback, M., Ditlev, S.B., Theander, T.G., et al. Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA. Infect Immun 77 (2009), 2482–2487.
14. [14] Bigey, P., Gnidehou, S., Doritchamou, J., Quiviger, M., Viwami, F., Couturier, A., et al. The NTS-DBL2X region of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several Plasmodium falciparum isolates to chondroitin sulfate A. J Infect Dis 204 (2011), 1125–1133.
15. [15] Nielsen, M.A., Resende, M., de Jongh, W.A., Ditlev, S.B., Mordmuller, B., Houard, S., et al. The influence of sub-unit composition and expression system on the functional antibody response in the development of a VAR2CSA based Plasmodium falciparum placental malaria vaccine. PLoS ONE, 10, 2015, e0135406.
16. [16] Thrane, S., Janitzek, C.M., Agerbaek, M.O., Ditlev, S.B., Resende, M., Nielsen, M.A., et al. A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA. PLoS ONE, 10, 2015, e0143071.
17. [17] Thrane, S., Janitzek, C.M., Matondo, S., Resende, M., Gustavsson, T., de Jongh, W.A., et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnol, 14, 2016, 30.
18. [18] Brune, K.D., Leneghan, D.B., Brian, I.J., Ishizuka, A.S., Bachmann, M.F., Draper, S.J., et al. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. Sci Rep, 6, 2016, 19234.
19. [19] FDA. Human Papillomavirus Vaccine.
20. [20] FDA. Hepatitis B Vaccine (Recombinant).
21. [21] Schmidt, M.R., McGinnes, L.W., Kenward, S.A., Willems, K.N., Woodland, R.T., Morrison, T.G., Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J Virol 86 (2012), 11654–11662.
22. [22] Nardin, E.H., Oliveira, G.A., Calvo-Calle, J.M., Wetzel, K., Maier, C., Birkett, A.J., et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 72 (2004), 6519–6527.
23. [23] Kumru, O.S., Joshi, S.B., Smith, D.E., Middaugh, C.R., Prusik, T., Volkin, D.B., Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals 42 (2014), 237–259.
24. [24] Thompson, C.M., Petiot, E., Mullick, A., Aucoin, M.G., Henry, O., Kamen, A.A., Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems. BMC Biotechnol, 15, 2015, 31.
25. [25] Andersson, A.C., Ragonnaud, E., Seaton, K.E., Sawant, S., Folgori, A., Colloca, S., et al. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. Vaccine 34 (2016), 5344–5351.
26. [26] Wang, B.Z., Liu, W., Kang, S.M., Alam, M., Huang, C., Ye, L., et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol 81 (2007), 10869–10878.
27. [27] Holst, P.J., Bartholdy, C., Stryhn, A., Thomsen, A.R., Christensen, J.P., Rapid and sustained CD4(+) T-cell-independent immunity from adenovirus-encoded vaccine antigens. J Gen Virol 88 (2007), 1708–1716.
28. [28] Kim, J.H., Lee, S.R., Li, L.H., Park, H.J., Park, J.H., Lee, K.Y., et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS ONE, 6, 2011, e18556.
29. [29] Wen, B., Deng, Y., Guan, J., Yan, W., Wang, Y., Tan, W., et al. Signal peptide replacements enhance expression and secretion of hepatitis C virus envelope glycoproteins. Acta Biochim Biophys Sin (Shanghai) 43 (2011), 96–102.
30. [30] Cottingham, M.G., Carroll, F., Morris, S.J., Turner, A.V., Vaughan, A.M., Kapulu, M.C., et al. Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnol Bioeng 109 (2012), 719–728.
31. [31] Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., Mehtali, M., Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70 (1996), 4805–4810.
32. [32] Becker, T.C., Noel, R.J., Coats, W.S., Gomez-Foix, A.M., Alam, T., Gerard, R.D., et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 43 Pt A (1994), 161–189.
33. [33] Andersen, P., Nielsen, M.A., Resende, M., Rask, T.S., Dahlback, M., Theander, T., et al. Structural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA. PLoS Pathog, 4, 2008, e42.
34. [34] Ditlev, S.B., Florea, R., Nielsen, M.A., Theander, T.G., Magez, S., Boeuf, P., et al. Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA. PLoS ONE, 9, 2014, e84981.
35. [35] Ragonnaud, E., Andersson, A.M., Pedersen, A.E., Laursen, H., Holst, P.J., An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4–1BBL leads to delayed tumor progression. Vaccine 34 (2016), 2147–2156.
36. [36] Wehrly, K., Chesebro, B., P24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods 12 (1997), 288–293.
37. [37] Haase, R.N., Megnekou, R., Lundquist, M., Ofori, M.F., Hviid, L., Staalsoe, T., Plasmodium falciparum parasites expressing pregnancy-specific variant surface antigens adhere strongly to the choriocarcinoma cell line BeWo. Infect Immun 74 (2006), 3035–3038.
38. [38] Snounou, G., Zhu, X., Siripoon, N., Jarra, W., Thaithong, S., Brown, K.N., et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 93 (1999), 369–374.
39. [39] Vzorov, A.N., Wang, L., Chen, J., Wang, B.Z., Compans, R.W., Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines. Virology 489 (2016), 141–150.
40. [40] Salanti, A., Clausen, T.M., Agerbaek, M.O., Al Nakouzi, N., Dahlback, M., Oo, H.Z., et al. Targeting human cancer by a glycosaminoglycan binding malaria protein. Cancer Cell 28 (2015), 500–514.
41. [41] Barfod, L., Dobrilovic, T., Magistrado, P., Khunrae, P., Viwami, F., Bruun, J., et al. Chondroitin sulfate A-adhering Plasmodium falciparum-infected erythrocytes express functionally important antibody epitopes shared by multiple variants. J Immunol 185 (2010), 7553–7561.
42. [42] Barman, S., Adhikary, L., Chakrabarti, A.K., Bernas, C., Kawaoka, Y., Nayak, D.P., Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding. J Virol 78 (2004), 5258–5269.
43. [43] Santos da Silva, E., Mulinge, M., Perez Bercoff, D., The frantic play of the concealed HIV envelope cytoplasmic tail. Retrovirology, 10, 2013, 54.
44. [44] Kim, S.H., Yan, Y., Samal, S.K., Role of the cytoplasmic tail amino acid sequences of Newcastle disease virus hemagglutinin-neuraminidase protein in virion incorporation, cell fusion, and pathogenicity. J Virol 83 (2009), 10250–10255.
45. [45] Schlie, K., Strecker, T., Garten, W., Maturation cleavage within the ectodomain of Lassa virus glycoprotein relies on stabilization by the cytoplasmic tail. FEBS Lett 584 (2010), 4379–4382.
46. [46] Edwards, T.G., Wyss, S., Reeves, J.D., Zolla-Pazner, S., Hoxie, J.A., Doms, R.W., et al. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 76 (2002), 2683–2691.
47. [47] Kabat, D., Gliniak, B., Rohrschneider, L., Polonoff, E., Cell anchorage determines whether mammary tumor virus glycoproteins are processed for plasma membranes or secretion. J Cell Biol 101 (1985), 2274–2283.